You are here
Articles on Gastrointestinal Cancer
A selection of peer-reviewed articles on Gastrointestinal Cancer. All content available on the Advances in Gastrointestinal Cancer Resource Center, including original and review articles, interviews, guidelines and congress highlights, is independently selected by the members of the Editorial Board.
Comprehensive geriatric assessment in patients with gastric and gastroesophageal adenocarcinoma undergoing gastrectomy
Pujara D, Mansfield P, Ajani J, Blum M, Elimova E, Chiang YJ, Das P, Badgwell B.J Surg Oncol. 2015 Oct 19.
L. Marano, K. Polom, A. Patriti, G. Roviello, G. Falco, A. Stracqualursi, R. De Luca, R. Petrioli, M. Martinotti, D. Generali, D. Marrelli, N. Di Martino, F. Roviello
European Journal of Surgical Oncology (EJSO), In Press, Corrected Proof, Available online 14 November 2015, Available online 14 November 2015
Phase II study of trastuzumab in combination with S-1 and cisplatin in the first-line treatment of human epidermal growth factor receptor HER2-positive advanced gastric cancer
Chua C, Tan IB, Yamada Y, Rha SY, Yong WP, Ong WS, et al.Cancer Chemother Pharmacol. 2015 Aug;76(2):397-408.
Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer
Shitara K, Muro K, Shimada Y, Hironaka S, Sugimoto N, Komatsu Y, et al.Gastric Cancer. 2015 Oct 28. [Epub ahead of print]
Impact of age on the feasibility and efficacy of neoadjuvant chemotherapy in patients with locally advanced oesophagogastric cancer
Lorenzen Sylvie, Spoerl Silvia, Al-Batran Salah-Eddin, Feith Markus, Lordick Florian, Thuss-Patience Peter, Haller Bernhard, Angele Martin, Novotny Alexander
European Journal of Cancer, Volume 51, Issue 14, September 2015, Pages 1918 - 1926
Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS)
Ryu MH, Baba E, Lee KH, Park YI, Boku N, Hyodo I,et al.Ann Oncol. 2015 Oct;26(10):2097-101
NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors
Schulz C, Kullmann F, Kunzmann V, Fuchs M, Geissler M, Vehling-Kaiser U, et al.Int J Cancer. 2015 Aug 1;137(3):678-85.
Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium
Shah MA, Janjigian YY, Stoller R, Shibata S, Kemeny M, Krishnamurthi S, et al.J Clin Oncol. 2015 Oct 5. [Epub ahead of print]
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial
Shapiro J, van Lanschot JJ, Hulshof MC, van Hagen P, van Berge Henegouwen MI, Wijnhoven BP, et al.Lancet Oncol. 2015 Sep;16(9):1090-8.